Drug intelligence / Profile preview

measles, mumps, and rubella vaccine (National Institute for Public Health and the Environment)

Development stage
Unknown
Lead developer
Merck
Modality
Vaccines & Immunotherapeutics
Administration
Subcutaneous, Intramuscular
01

Overview

The MMR vaccine is a live attenuated combination vaccine designed to provide immunity against measles, mumps, and rubella. It contains weakened strains of the measles virus (typically Schwarz or Edmonston-Zagreb strains), mumps virus (such as Jeryl Lynn or RIT 4385), and rubella virus (usually RA 27/3). Administered primarily to children in a two-dose schedule, the vaccine stimulates both humoral and cellular immune responses. It has been a cornerstone of public health programs globally since the 1970s, significantly reducing the incidence of these viral infections and their associated complications. In the Netherlands, it is known as the BMR vaccine and is managed by the RIVM, which has conducted specific observational studies (BMR-0 and BMR-1) to evaluate immunological responses during outbreaks and regular immunization schedules.

Brand names
M-M-R IIPriorixTrimovaxVaxPro
Other names
MMR vaccineBMR vaccinemeasles-mumps-rubella vaccine
02

Targets

Mumps virus antigenMV (Measles virus)

Beyond the preview

Go deeper on measles, mumps, and rubella vaccine (National Institute for Public Health and the Environment).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on measles, mumps, and rubella vaccine (National Institute for Public Health and the Environment).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call